AstraZeneca COVID-19 vaccine applies for full regulatory approval in Brazil


  • World
  • Saturday, 30 Jan 2021

FILE PHOTO: A test tube labelled "vaccine" in front of an AstraZeneca logo in this illustration taken, September 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

RIO DE JANEIRO (Reuters) - Brazilian health regulator Anvisa said on Friday that a COVID-19 vaccine developed by Oxford University and AstraZeneca Plc had applied for full regulatory approval, in a positive development for the country's beleaguered vaccine rollout.

The submission, the first of its kind in Brazil, was made by the federally funded Fiocruz Institute, which will manufacture the British vaccine locally. A spokeswoman for AstraZeneca, whose vaccine is already approved for emergency use in Brazil, confirmed the submission.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

Russian attack injures six people in Ukraine's Kharkiv, governor says
Prabowo vows to fight for all Indonesians, calls for unity among political elites
Russian priest presiding over Navalny's memorial suspended from duties
These apps allow US workers to get paid between paychecks. Experts say there are steep costs
Cyberattacks are on the rise, and that includes small businesses. Here’s what to know
Myanmar rebel group withdraws troops from key town on Thai border
Recycled ‘zombie’ misinformation targets US voters
Fire, evacuation after Ukraine drone attacks on Russia's Smolensk, Lipetsk
Apple to hold launch event on May 7, with new iPads expected
Musk targets Australian senator, gun laws in deepening dispute over X stabbing content

Others Also Read